Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants
Authors:
- 1 July 2000
- journal article
- case report
- Published by Wolters Kluwer Health in Hepatology
- Vol. 32 (1) , 129-134
Abstract
Lamivudine has been shown to be an effective therapy for chronic hepatitis B, but resistance to this nucleoside agent is common after prolonged use. Five patients with chronic hepatitis B virus (HBV) infection developed resistance to lamivudine after 9 to 19 months of treatment. In 4 patients this occurred after liver transplantation and the remaining individual had stable cirrhosis. In each case, resistance was confirmed to be caused by one or more mutations in the HBV-DNA polymerase gene and was associated with active underlying liver disease. The patients were treated with adefovir dipivoxil in a dose of 5 to 30 mg daily. Two to 4 log10 reductions in HBV-DNA levels were observed in 4 cases, and the fifth patient became negative by quantitative polymerase chain reaction (PCR) after retransplantation in conjunction with hepatitis B immunoglobulin (HBIg). Virologic improvement was associated with stable or declining serum alanine transaminase levels in 4 patients. HBV-DNA suppression has been sustained during a mean treatment period of 13 months (range 11 to 15 months), including 1 patient in whom lamivudine has been discontinued. Mild changes in renal function were observed during treatment in most cases but did not require early discontinuation of the drug. This study provides evidence that adefovir dipivoxil can be an effective treatment for lamivudine-resistant HBV mutants as well as wild-type HBV.Keywords
This publication has 16 references indexed in Scilit:
- Efficacy and Safety of Adefovir Dipivoxil With Antiretroviral TherapyA Randomized Controlled TrialJAMA, 1999
- Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under hbig immunoglobulin after liver transplantationHepatology, 1999
- Multicenter Study of Lamivudine Therapy for Hepatitis B After Liver TransplantationHepatology, 1999
- Lamivudine and intron a combination treatment in patients with chronic hepatitis B infectionJournal of Hepatology, 1998
- Mutations in Hepatitis B Dna Polymerase Associated With Resistance to Lamivudine Do Not Confer Resistance to Adefovir In VitroHepatology, 1998
- A One-Year Trial of Lamivudine for Chronic Hepatitis BNew England Journal of Medicine, 1998
- Identification and characterization of mutations in hepatitis B virus resistant to lamivudineHepatology, 1998
- Two-year lamivudine therapy in chronic hepatitis B infection: Results of a placebo controlled multicentre study in AsiaGastroenterology, 1998
- Famciclovir treatment in lamivudine resistent chronic hepatitis B patientsJournal of Hepatology, 1998
- Immunogencity of two versus three injections of inactivated hepatitis A vaccine in adultsJournal of Hepatology, 1997